A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms SOPRANO
- Sponsors Actelion Pharmaceuticals
- 21 Nov 2017 Planned number of patients changed from 64 to 78.
- 10 Jun 2017 Biomarkers information updated
- 08 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.